Business Wire: Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, featuring Peter Houghton, Ph.D.
- Webinar to be hosted on Thursday, Sept. 22, 2022, at 12:00 p.m. ET, register here.
- Dr. Houghton will discuss challenges in drug development for pediatric cancers and preliminary results from Lantern’s drug candidates in preclinical pediatric cancer models with unmet clinical needs.
September 19, 2022 08:50 AM Eastern Daylight Time
DALLAS–(BUSINESS WIRE)–Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host a virtual key opinion leader (KOL) webinar on Sept. 22, 2022 at 12:00 p.m. ET. The webinar will focus on challenges in drug development for pediatric cancers and the potential of Lantern’s drug candidates LP-184 and LP-284 for several rare pediatric cancers.
The webcast will feature a leading expert in pediatric cancer research, Peter Houghton, Ph.D., Professor & Principal Investigator at Greehey Children’s Cancer Research Institute (Greehey CCRI) at UT Health Science Center-San Antonio. During the webcast, Dr. Houghton will discuss the disparities and hurdles that currently exist in pediatric cancer research, drug development, and clinical trial design compared to adults. He will also provide details on exciting new preclinical results for LP-284 and its preclinical efficacy in vivo for several pediatric cancer models, including Ewing’s sarcoma, malignant rhabdoid tumors, and alveolar rhabdomyosarcomas. Details on the webinar and how to register can be found below:
Read the full text here.